

1,2-dihydropyridin-2-one; 1-methyl-4-[4-methyl-5-({3-[1-(2,4,6-trifluorophenyl)-octahydropyrrolo[2,3-c]pyrrol-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-one; 4-[5-({3-[(3aS,6aS)-1-(2,4,6-trifluorophenyl)-octahydropyrrolo[2,3-c]pyrrol-5-yl]propyl}sulfanyl)-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl-1,2-dihydropyridin-2-one; 4-[5-({3-[(3aR,6aR)-1-(2,4,6-trifluorophenyl)-octahydropyrrolo[2,3-c]pyrrol-5-yl]propyl}sulfanyl)-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl-1,2-dihydropyridin-2-one; 4-{4-methyl-5-[(3-{1-[4-(trifluoromethyl)phenyl]-octahydropyrrolo[2,3-c]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}cyclohexan-1-ol; 4-[5-({3-[(3aS,6aS)-1-[4-(trifluoromethyl)phenyl]-octahydropyrrolo[2,3-c]pyrrol-5-yl]propyl}sulfanyl)-4-methyl-4H-1,2,4-triazol-3-yl]cyclohexan-1-ol; 4-[5-({3-[(3aS,6aS)-1-[4-(trifluoromethyl)phenyl]-octahydropyrrolo[2,3-c]pyrrol-5-yl]propyl}sulfanyl)-4-methyl-4H-1,2,4-triazol-3-yl]cyclohexan-1-ol; 4-methyl-3-(4-methyl-1,3-oxazol-5-yl)-5-({3-[(4S)-4-[4-(trifluoromethyl)phenyl]-octahydrocyclopenta[c]pyrrol-2-yl]propyl}sulfanyl)-4H-1,2,4-triazole; 3-({3-[(4aS,7aS)-1-[4-(trifluoromethyl)phenyl]-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]propyl}sulfanyl)-4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazole; and a pharmaceutical acceptable salt of any one of the foregoing.

19. A compound of any one of claims 1 to 18 or a pharmaceutical acceptable salt thereof for use as a medicament.

20. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 18 and a pharmaceutically acceptable carrier.

21. A compound of any one of claims 1 to 18 for the use in the treatment of a condition for which modulation of dopamine D₃ receptors is beneficial.

22. A compound according to claim 21 in which the condition is psychosis or a psychotic condition, or is substance abuse.

23. A compound according to claim 22 in which the condition is schizophrenia.

24. Use of a compound of any one of Claims 1 to 18 in the manufacture of a medicament for treating drug dependency.

25. The use of claim 24, wherein the drug dependency is alcohol dependency.
26. The use of claim 24, wherein the drug dependency is opioid dependency.
27. Use of a compound of any one of Claims 1 to 18 in the manufacture of a medicament for treating an addiction.
28. The use of claim 27, wherein the addiction is a drug addiction.
29. The use of claim 27, wherein the addiction is gambling.
30. Use of a compound of any one of Claims 1 to 18 in the manufacture of a medicament for treating a psychiatric condition.
31. Use of a compound of any one of Claims 1 to 18 in the manufacture of a medicament for modulating a dopamine D₃ receptor.
32. The use of claim 31, wherein the modulating the dopamine D₃ receptor is antagonizing the dopamine D₃ receptor.
33. The use of claim 31 or 32, wherein modulating the dopamine D₃ receptor is treating a medical condition that is impacted by the dopamine D₃ receptor.